UK AIM- and US NASDAQ-quoted Mereo BioPharma Group PLC has raised $70m (£56m) from US investors, saying it will start a Phase Ib trial with etigilimab, its anticancer TIGIT inhibitor, in the fourth quarter of 2020, and seek a partner for its Phase III-ready lead product setrusumab for treatment of osteogenesis imperfecta.
Shares in the London, UK and Redwood City, CA-based biotech doubled to 50p on AIM on 4 June, when completion...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?